UM-211 blood pressure monitor is designed to measure systolic, diastolic pressure, and pulse rate of adults who are twelve (12) years and older in the clinics and hospitals. The arm size is from 16 cm (6.3 inches) to 50 cm (19.7 inches). UM-211 can measure blood pressure in auscultatory (device class DXQ) and oscillometric (device class DXN) methods. It can detect irregular heartbeats and display a symbol on its display.

Device Description

UM-211 Digital Blood Pressure Monitors have the same design as the predicate devices with an inflatable cuff which is wrapped around the patient's upper arm. The blood pressure measurement starts with the inflation process by an internal pump. The systolic and diastolic blood pressures are determined by oscillometric method during the deflation process. The deflation rate is controlled by an internal exhaust valve. There is a quick exhaust mechanism so that the cuff pressure can be completely released immediately. Furthermore, there is a maximum pressure safety setting at 299 mmHg. UM-211 Digital Blood Pressure Monitor will not inflate the cuff higher than 299 mmHg. UM-211 will turn on an irregular heartbeat indicator if an irregular heartbeat was detected during the measurement process. For the oscillometric method, systolic and diastolic are determined by the internal algorithm. For the auscultatory method, systolic and diastolic are determined by the medical professionals. The results are shown on the LCD. The cuff is also deflated automatically to 0 mmHg at the same time. This auscultatory method is identical to the predicate device, UM-101 digital blood pressure monitor. The oscillometric method is identical to the predicate device with the capability to perform averaging function of multiple measurements (AOBP mode).

UM-211 also detects the patient daily activities and environmental conditions of ambient temperature and barometric pressure. These are non-medical features which will be only available for the medical professionals to review. These information are not displayed to the patient on the TM-2441 display. The BP waveform is another non-medical feature which can be used by the medical professional and A&D engineers to verify the accuracy of the blood pressure measurement. Basically, we can reconstruct the systolic, and pulse rate from the BP waveform. There is no other medical diagnose from the information of the BP waveform.

If the monitor receives no further action from the user for 1 minute, it will automatically turn off by itself and waiting for the next measurement timing. UM-211 has a memory capacity of 99 for the previous measurements.

AI/ML Overview

The provided document describes the A&D Medical UM-211 Digital Blood Pressure Monitor, a non-invasive blood pressure measurement system.

Here's an analysis of the acceptance criteria and study information:

1. Table of Acceptance Criteria and Reported Device Performance

Standard Requirement (Acceptance Criteria)	Reported Device Performance (Test Result)	Result
Criterion 1: Mean value ± 5 mmHg or less	Mean value: SYS = 3.05 mmHg, DIA = 2.87 mmHg	Passed
Criterion 1: Standard deviation 8 mmHg or less	Std Deviation: SYS = 3.59 mmHg, DIA = 3.48 mmHg	Passed
Criterion 2: Standard deviation SYS=6.20 mmHg or less, DIA=6.30 mmHg or less	Std Deviation: SYS = 3.50 mmHg, DIA = 3.11 mmHg	Passed

Note: The table for "Criterion 2" in the original document appears to have values under "Standard Requirements" that are actually performance metrics (SYS=6.20, DIA=6.30 or less) rather than a specified standard requirement. I've interpreted these as another set of limits for standard deviation that the device performance should meet.

2. Sample Size Used for the Test Set and Data Provenance

The document does not explicitly state the sample size (number of participants) used for the clinical blood pressure measurement study. It also does not specify the country of origin of the data or whether the study was retrospective or prospective.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

This information is not provided in the document. For blood pressure monitors, the "ground truth" (reference measurement) is typically established by trained observers using a mercury sphygmomanometer or another validated reference device, following specific protocols (e.g., simultaneous arm measurements). The document only states that "Clinical BP Measurement: ISO 81060-2:2013" was performed, which implies these procedures were followed.

4. Adjudication Method for the Test Set

The document does not describe any specific adjudication method. For blood pressure measurement validation studies, ground truth is usually established by multiple observers independently taking measurements, with averaged or expert-adjudicated readings used as the reference. However, the exact method is not detailed here.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size of Human Improvement with AI vs. Without AI Assistance

No, an MRMC comparative effectiveness study was not done. This device is a digital blood pressure monitor, not an AI-assisted diagnostic tool for which human-in-the-loop performance is typically assessed in this manner.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, a standalone performance assessment was conducted. The accuracy of the UM-211 Digital Blood Pressure Monitor (an algorithm-based device for oscillometric measurement) was evaluated against established standards (ISO 81060-2:2013) to determine its ability to measure blood pressure independently.

7. The Type of Ground Truth Used

The ground truth used for the clinical blood pressure measurement was based on highly accurate reference measurements, as dictated by the ISO 81060-2:2013 standard. This standard specifies the requirements for the clinical validation of automated non-invasive sphygmomanometers, which typically involves comparing the device's readings to those obtained simultaneously by trained observers using a reference method (e.g., auscultatory method with a mercury sphygmomanometer).

8. The Sample Size for the Training Set

The document does not explicitly mention a separate "training set" or its size. For medical devices like this, the device's
internal algorithm for oscillometric measurement would have been developed and refined using extensive data, but this
document focuses on the validation of the final device, not the details of its developmental training.

9. How the Ground Truth for the Training Set Was Established

Since a "training set" is not explicitly discussed for this specific device validation, the method for establishing its
ground truth is not provided. However, for the development of such devices, ground truth for training data would
typically be established using the same principles as the validation ground truth: comparison to highly accurate
reference measurements (e.g., auscultatory readings) performed by human experts.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the text "U.S. Food & Drug Administration" in blue letters.

March 21, 2019

A&D Company, Ltd. Jerry Wang Director of Engineering 1756 Automation Parkway San Jose, California 95131

Re: K173191

Trade/Device Name: A&D Medical UM-211 Digital Blood Pressure Monitor Regulation Number: 21 CFR 870.1130 Regulation Name: Noninvasive Blood Pressure Measurement System Regulatory Class: Class II Product Code: DXN Dated: February 20, 2019 Received: February 22, 2019

Dear Jerry Wang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Shawn W. Forrest -S 2019.03.21 12:35:17 -04'00'

for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K173191

Device Name

A&D Medical UM-211 Digital Blood Pressure Monitor

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summarv

This summary of 510(k) safety and effective information is being submitted in accordance with the requirement of SMDA and 21 CFR 807.92.

Date Prepared 1.

March 22, 2018

2. Submitter's Information

A&D Engineering, Inc. Mr. Jerry Wang 1756 Automation Parkway, San Jose, CA 95131 Tel: 408-334-3326 Email: jwang@aandonline.com

Device Information 3.

Proprietary Name:	A&D Medical UM-211 Digital Blood Pressure Monitor
Regulation Number:	21 CFR 870.1130
Regulation Name:	Noninvasive Blood Pressure Measurement System
Regulatory Class:	Class II
Product Code:	DXQ & DNX

4. Information of the Predicate Devices

A&D Medical UM-101 Digital Blood Pressure Monitor with 510(k) number K061456 ●
A&D Medical UA-1000 Series Digital Blood Pressure Monitors with 510(k) number ● K111686

ડ. Indications for Use

6. Intended Use

A&D Medical UM-211 Digital Blood Pressure Monitor is designed at clinics and hospitals by medical professionals to measure blood pressure of patients defined in the Indications for Use above.

7. Device Description - Technological and Operational Characteristics Comparison

{4}------------------------------------------------

systolic and diastolic are determined by the medical professionals. The results are shown on the LCD. The cuff is also deflated automatically to 0 mmHg at the same time. This auscultatory method is identical to the predicate device, UM-101 digital blood pressure monitor. The oscillometric method is identical to the predicate device with the capability to perform averaging function of multiple measurements (AOBP mode).

8. Summary of Substantial Equivalence Modifications made from the predicate devices (UM-101 & UA-1000 series):

· Modify the external industrial design for a different appearance.
· Modify the internal layout of the circuit and components.
· Increase the number of supported cuff size from 3 sizes to 4 sizes.
· Power source Adding rechargeable battery
· Combine the oscillometric and auscultatory methods

Discussion of standards used in the design verification and design validation

A&D Medical conducted design verification and design validation activities based on the comparison of the UM-211 with the predicate devices. Based on the changes, we conducted the appropriated test methodology and pass/fail criteria. After the tests were conducted, the test records were collected in the UM series design history file (DHF).

A&D Medical follows FDA recognized consensus standards and guidance documents in our medical device development and manufacturing processes. The following standards were used to for the design verification and valuation of UM series digital blood pressure monitors. These standards include three major groups. First group is the general quality system requirements. Second group is the special requirements for CDRH (870.1130). The third group is related to software and app life cycle processes requirements.

AAMI/ANSI/ISO 14971:2007/(R) 2010 (Corrected 4 October 2007) ● Medical Devices - Applications Of Risk Management To Medical Devices (FDA Recognized Number 5-70)
. AAMI/ANSI/IEC 60601-1-2:2007/(R)2012 Medical Electrical Equipment - Part 1-2: General Requirements For Basic Safety And Essential Performance - Collateral Standard: Electromagnetic Compatibility -Requirements And Tests (Edition 3) (FDA Recognized Number 19-2)
AAMI/ANSI/IEC 80601-2-30:2009 & A1:2013

{5}------------------------------------------------

Medical Electrical Equipment - Part 2-30: Particular Requirements For The Basic Safety And Essential Performance Of Automated Noninvasive Sphygmomanometers (FDA Recognized Number 3-130)

AAMI/ANSI/IEC 62304:2006 Medical Device Software - Software Life Cycle Processes (FDA Recognized Number 13-32)

9. Substantial Equivalence Conclusion:

Test Summary based on FDA recognized standards:

Safety & EMC Tests: IEC 60601-1-2 Edition 3: 2007-03 ●
ASMI/ANSI/IEC 80601-2-30:2009 & A1:2013 . Reliability Tests:
Risk Assessment: . ISO 14971:2012
Software Assessment:
Clinical BP Measurement: ISO 81060-2:2013 ●

The summary of the test results of ISO 81061-2 is listed below. UM series passed all blood pressure measurement accuracy requirements.

Standard Requirements	Test Result	Result
Criterion 1:Mean value &Standard deviation	Mean : ± 5mmHgor lessS. D. : 8mmHg orless	Mean value: SYS = 3.05 mmHgDIA = 2.87 mmHgStd deviation: SYS = 3.59 mmHgDIA = 3.48 mmHg	Passed
	Criterion 2:Standard deviation	SYS=6.20,DIA=6.30 or less	Std deviation: SYS = 3.50 mmHgDIA = 3.11 mmHg

UM-211 met all applicable requirements of the FDA recognized consensus standards and guidance documents. None of the test demonstrated that UM-211 brings new issues of safety and effectiveness.

As a conclusion, UM-211 digital blood pressure monitor as described in its labeling and comparison analysis has not changed because of the modifications. The fundamental scientific technology of the modified device has not changed, either. There is no significant difference that affects the safety or effectiveness of the modified device as compared to the predicate devices.

Regulation Number and Section

§ 870.1130 Noninvasive blood pressure measurement system.

(a)
Identification. A noninvasive blood pressure measurement system is a device that provides a signal from which systolic, diastolic, mean, or any combination of the three pressures can be derived through the use of tranducers placed on the surface of the body.(b)
Classification. Class II (performance standards).